This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mucolytics

Authoring team

Mucolytics are used in the reduction of sputum viscosity, and thus are given to help expectoration in chronic asthma and bronchitis.

Types of mucolytics, listed as synonyms, include:

  • acetlycysteine
  • carbocisteine
  • methylcysteine hydrochloride

Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation, and pathophysiologically involves many components including mucus hypersecretion, oxidative stress, and inflammation in the airway and lungs

  • in Europe and Asia, mucolytics such as carbocisteine have been widely used for treatment of respiratory diseases with phlegm production because of their capacity to facilitate sputum elimination
    • carbocisteine seems likely to have a role in antioxidation and and anti-inflammation that might be more important than mucolysis itself for long-term management of COPD
    • clinical studies have shown benefits in preventing exacerbation of COPD with carbocisteine
  • the PEACE study revealed that:
    • 1-year management of carbocisteine was effective for COPD patients in terms of reductions in exacerbations and improvements in quality of life
    • no interactions between treatment and COPD severity, smoking status, and concomitant use of inhaled corticosteroids
    • authors concluded that mucolytics, such as carbocisteine, should be recognised as a worthwhile treatment for the long-term management of COPD

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.